

1 **Rapid response flow cytometric assay for the detection of antibody**
2 **responses to SARS-CoV-2**

3 **Dennis Lapuente¹, Clara Maier¹, Pascal Irrgang¹, Julian Hübner¹, Sophia Peter¹,**
4 **Markus Hoffmann², Armin Ensser¹, Katharina Ziegler³, Thomas H. Winkler⁴, Torsten**
5 **Birkholz⁵, Andreas E. Kremer⁶, Philipp Steininger¹, Klaus Korn¹, Frank Neipel¹, Klaus**
6 **Überla¹, Matthias Tenbusch¹**

7 ¹ Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-
8 Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; ² Infection Biology
9 Unit, German Primate Center - Leibniz Institute for Primate Research, 37077 Göttingen,
10 Germany; ³ Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus
11 Medical University, Nürnberg, Germany; ⁴ Department of Biology, Division of Genetics,
12 Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander University Erlangen-
13 Nürnberg, Erlangen, Germany; ⁵ Department of Anaesthesiology, University Hospital
14 Erlangen, Erlangen, Germany; ⁶ Department of Medicine 1, Gastroenterology, Pneumology
15 and Endocrinology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-
16 Nürnberg, 91054 Erlangen, Germany; Address for correspondence: Dennis Lapuente, Institute
17 of Clinical and Molecular Virology, University Hospital Erlangen, Schlossgarten 4, 91054
18 Erlangen, Germany; E-mail: Dennis.Lapuente@uk-erlangen.de

19

20 **Abstract**

21 SARS-CoV-2 has emerged as a previously unknown zoonotic coronavirus that spread
22 worldwide causing a serious pandemic. While reliable nucleic acid-based diagnostic assays
23 were rapidly available, there exists only a limited number of validated serological assays.
24 Here, we evaluated a novel flow cytometric approach based on antigen-expressing HEK 293T
25 cells to assess spike-specific IgG and IgM antibody responses. Analyses of 201 pre-COVID-
26 19 sera proved a high assay specificity in comparison to commercially available CLIA and
27 ELISA systems, while also revealing the highest sensitivity in specimens from PCR-
28 confirmed SARS-CoV-2 infected patients. Additionally, a soluble Angiotensin-Converting-
29 Enzyme 2 (ACE-2) variant was established as external standard to quantify spike-specific
30 antibody responses on different assay platforms. In conclusion, our newly established flow
31 cytometric assay allows sensitive and quantitative detection of SARS-CoV-2-specific

32 antibodies, which can be easily adopted in different laboratories and does not rely on external
33 supply of assay kits.

34 **Introduction**

35 In early December 2019, a novel zoonotic coronavirus (CoV) caused a cluster of pneumonia
36 cases in Wuhan, China (1). Since then, the virus has spread globally and caused a pandemic
37 with over 3,435,000 confirmed infections and about 240,000 fatalities (as of May 4th 2020)
38 (2). Due to its phylogenetic similarity to the Severe Acute Respiratory Syndrome Related
39 Coronavirus (SARS-CoV-1), the novel CoV was named SARS-CoV-2 (3). The acute
40 respiratory disease induced by SARS-CoV-2 is called coronavirus disease 19 (COVID-19).

41 The identification of acutely infected individuals by the detection of viral RNA by real-time
42 PCR (4) was implemented rapidly in the health care of most countries. While this method is
43 highly valuable for the diagnosis of acute COVID-19 cases, specific serological methods are
44 urgently needed to determine seroconversion in general and more specifically to characterize
45 the humoral response against SARS-CoV-2. Robust, validated serological approaches are
46 essential to track transmission events in individuals that have already cleared the infection
47 especially after mild or symptom-free disease. With increasing numbers of immune
48 individuals, serological tests will also help to understand epidemiological aspects of the
49 pandemic and to employ SARS-CoV-2 immune staff in critical frontline positions at hospitals
50 or nursing homes. In addition, validated serological methods are essential to evaluate novel
51 vaccine candidates in clinical studies.

52 Together with the 2003 SARS-CoV-1 and the 2012 Middle East Respiratory Syndrome
53 Coronavirus (MERS-CoV) epidemic, the SARS-CoV-2 pandemic represents the third
54 betacoronavirus in twenty years that crossed the species barrier and resulted in a significant
55 number of human infections. At the same time, four other CoVs are endemic in the human
56 population (two alphacoronaviruses: CoV-NL63 and -229E, two betacoronaviruses: CoV-

57 OC43 and -HKU1) that cause episodes of common cold in humans in all parts of the world
58 (5). CoVs are enveloped single-stranded RNA viruses that contain four structural proteins:
59 membrane (M), envelope (E), spike (S), and nucleocapsid (N). From SARS-CoV-1 it is
60 known that N and S proteins are the most immunogenic viral antigens, while only S-specific
61 antibodies can mediate virus neutralization (6,7). Therefore, N- and S-specific antibody
62 responses should be first choice parameters for a sensitive serology (8). However, depending
63 on the study cohort, up to 90% of the population is seropositive for common cold CoVs (9–
64 11). Thus, a careful validation of the assay specificity is required in CoV serology.

65 Here, we describe a novel flow cytometric assay to determine SARS-CoV-2 spike protein-
66 specific antibodies in serum samples. The virus-free assay relies on reagents and devices that
67 are available in many medical and biological research labs and therefore can be easily adopted
68 in a decentral manner without the need for commercial kits or products that are prone to
69 shortage.

70 **Materials and methods**

71 **Serum samples**

72 Anonymized, random sera (n=180) were selected from the sample repository of the
73 diagnostics department of the Institute for Clinical and Molecular Virology at the University
74 Hospital Erlangen to evaluate the specificity of the novel diagnostic test. Samples were
75 collected until August 2019 (further denominated as pre-COVID-19 era) and no longer
76 needed for diagnostic purposes and assigned for disposal. Those specimens were not
77 characterized in regard to anti-HCoV antibody status. 21 sera from eight patients with PCR-
78 confirmed endemic HCoV infections were additionally included. These samples were
79 collected at least one week before and two to four weeks after HCoV infection. These include
80 4x HKU-1, 2x 229E, 1x NL63, 1x OC43 infections. Post-infection sera were sampled twice
81 from some patients (Table 1). Additionally, 60 specimens from 34 individuals with a PCR-

82 confirmed SARS-CoV-2 infection (some sampled longitudinally) were obtained. The majority
83 is derived from a newly established biobank for COVID-19 patients at the University Hospital
84 Erlangen. The data are collected in accordance with ethical requirements. The
85 implementation of the biobank has been approved by the local ethics committee of the UK
86 Erlangen under the licence number AZ. 174_20 B. Five out of 60 were derived from plasma
87 donors after (patients' informed consents; approved by local ethics committee of the FAU;
88 AZ. 2020, 49_20B). Another set of sera was collected from thirteen COVID-19 patients at the
89 Hospital Nürnberg Nord at different time points after the PCR-confirmation (Table 2). All
90 sera were sampled for recent diagnostic purpose and have been tested for seroconversion in
91 the EuroImmun ELISA at the Institute of Clinical Hygiene, Medical Microbiology and
92 Infectiology, Paracelsus Medical University, Hospital Nürnberg, Germany. All clinical
93 specimen were used in anonymous form for retrospective analyses.

94 **DNA plasmids**

95 The pCG1_CoV_2019-S plasmid encoding the codon-optimized sequence of the SARS-CoV-
96 2 S protein was generated as described elsewhere (12). The plasmid pcDNA3.1 (Invitrogen)
97 was used in the mock transfection control. Blue fluorescent protein (BFP) and red fluorescent
98 protein-encoding (dsRed; from *Discosoma sp.*) plasmids were used as marker proteins for
99 transfected 293T cells.

100 **Flow cytometric antibody assay**

101 Human embryonic kidney cells (HEK 293T cells; ECACC 12022001) were maintained in
102 Dulbecco's modified Eagle's medium (DMEM; Gibco, Cat #11960-044) containing 10% fetal
103 calf serum (Capricorn Scientific, Cat #FBS-12A), 1% GlutaMAX (Gibco, Cat #35050-038),
104 and 1% Penicillin/Streptomycin (Gibco, Cat #15140-122) at 37°C and 5% CO₂. For the assay,
105 1.12×10^7 cells were plated out (25 ml medium; 175 cm² cell culture flask) and, 12-24 hours
106 later, were transfected with 30 µg pCG1_CoV_2019-S plus 15 µg fluorescent protein (BFP)

107 by standard polyethylenimine transfection (3.5 ml DMEM, 67.5 µg polyethylenimine). As an
108 internal control, a mock transfection was used with 30µg pcDNA3.1 and 15µg fluorescent
109 protein (dsRed). 48 hours after the transfection, cells were harvested, resuspended in freeze
110 medium (75% FCS, 10% DMSO, 3% Glucose in DMEM), and stored in 1 ml aliquots of
111 1×10^7 cells at -80°C .

112 For the assay, aliquots of cells were thawed, washed once with PBS, and then resuspended in
113 FACS buffer (PBS with 0.5% bovine serum albumin and 1 nmol sodium azide). 0.5×10^5 cells
114 of each of the two cell preparations (S- and mock-transfected) were seeded out per sample in
115 a 96-well U-bottom plate. Serial dilutions of the standards or serum samples (1:100) were
116 diluted in 100 µl FACS buffer and given on the cells (30 min, 4°C). 100 µl FACS buffer was
117 added, cells were centrifuged (500 xg, 4°C , 3min; used for all following centrifugation steps),
118 washed two times with 180 µl FACS buffer, and bound antibodies were stained with
119 secondary detection antibodies diluted 1:300 in 100 µl FACS buffer (30 min, 4°C , anti-IgG-
120 AF647, clone HP6017, Biolegend, Cat #409320; anti-IgM-BV711, clone MHM-88,
121 Biolegend, Cat #314540). 100 µl PBS was added, cells were centrifuged, washed two times
122 with 180 µl PBS, and fixed in 200 µl 2% paraformaldehyde in PBS (15 min, 4°C). Cells were
123 centrifuged and washed once in 180 µl FACS buffer, before resuspended in 200 µl FACS
124 buffer for flow cytometric analysis. Data were acquired on a BD LSR II or Thermo Fisher
125 Attune Nxt cytometer and analysis was performed with FlowJo (Tree Star Inc.) or Flowlogic
126 (Inivai Technologies).

127 **ACE-2-Fc standard**

128 A PCR fragment containing the sequence coding for the extracellular domain of human ACE-
129 2 lacking the secretory signal peptide (NM_021804.3, nucleotides 358 – 2520) fused at the 3'
130 end with a PCR fragment coding for the Fc-part of human IgG1 and a C-terminal myc/his tag
131 was cloned into the expression vector pCEP4 (Thermo Fisher Scientific). The signal peptide

132 of the murine IgG kappa-chain V-J2 was used instead of the ACE-2 signal peptide. The
133 synthetic intron from pIRES (IVS, Takara Bio) was cloned via NheI restriction sites between
134 the transcription start and the translation start site. Expression and purification of the Fc-
135 fusion protein was done as described before (13). Briefly, HEK 293T cells were transfected
136 by calcium phosphate method and kept in culture for six days. Cell culture supernatant was
137 then harvested and cell debris removed by centrifugation. The pH of the supernatant was
138 adjusted to 8.0 with NaOH and sterile filtered. The supernatant was then applied to a HiTrap
139 Protein A HP column (GE Healthcare Life Sciences). ACE-2-Fc fusion protein was eluted by
140 a pH step gradient using 0.1 M citrate buffer. ACE-2 Fc fusion protein eluted at pH 4.0 and
141 the pH was immediately neutralized by the addition of 1M Tris buffer (pH 9).

142 As an external standard for IgG quantitation, a two-fold dilution series starting with 10 µg/ml
143 of ACE-2-Fc was measured in the flow cytometric assay as described above. With this
144 standard, we quantified the amount of ACE-2-binding equivalents in a plasma sample
145 available in larger volume. Adjusting for molecular weight differences between ACE2-Fc and
146 IgG, the anti-SARS-CoV-2 S IgG concentration in this plasma sample was determined.

147 **Enzyme-linked Immunosorbent Assay (ELISA)**

148 Commercially available ELISA for the detection of anti-SARS-CoV-2 IgG (anti-S1-specific,
149 EuroImmun, Cat #EI 2606-9601 G) and IgA (EuroImmun, Cat #EI 2606-9601 A) were
150 performed according to the manufacturer's protocols. Sera were diluted 1:101 (10µl sample +
151 1000µl sample buffer) and the optical density was detected at 450 nm at a multilabel plate
152 reader (Victor X5, Perkin Elmer). A cut-off for a positive result was according to the
153 manufacturer defined as a ratio of >1.1 between the specific specimen and the calibrator.
154 Values between 0.8 and 1.1 were defined as "borderline".

155 **Chemiluminescent Immunoassay (CLIA)**

156 Commercially available magnetic bead-based CLIA for the detection of IgG (N- and S-
157 specific, Shenzhen Yhlo Biotech, iFlash-SARS-CoV-2, Cat #C86095G) and IgM (Shenzhen
158 Yhlo Biotech, iFlash-SARS-CoV-2, Cat #C86095M) were performed on a fully automated
159 iFlash Immunoassay Analyzer (Shenzhen Yhlo Biotech). The assays were performed
160 according to the manufacturer's protocols. The IgG and IgM titer were automatically
161 calculated as arbitrary units (AU/ml) and the cut-off value for a positive test was 10 AU/ml.

162 **Results**

163 **Assay specificity for SARS-CoV-2 immune sera**

164 The novel serological assay we evaluate here exploits 293T cells that express full-length
165 SARS-CoV-2 spike protein in its natural conformation to bind antigen-specific IgM and IgG
166 from patient sera with a subsequent quantification by secondary detection antibodies. In a
167 multiplex approach with two populations each co-expressing a specific fluorescent protein
168 (dsRed or BFP), non-antigen-expressing cells provide an internal specificity control. By this,
169 one can control for unspecific binding of antibodies to cellular components leading to
170 potentially false-positive results for example in patients with autoimmune diseases.

171 Figure 1 illustrates the gating strategy and the respective IgM and IgG mean fluorescence
172 intensity (MFI) signals for three negative controls and three SARS-CoV-2 convalescent sera.
173 None of the negative control sera S4-S6 led to a significant MFI increase in the S-expressing
174 population compared to the mock control cells. In contrast, both for IgM and IgG, the MFI in
175 the S-expressing cells were clearly increased compared to the mock cells indicating a specific
176 binding of S-specific antibodies. Subsequently, we defined two cut-off criteria for a positive
177 serological result: (i) the MFI of the test sample must be at least three-fold higher compared to
178 the mean of three negative sera tested in parallel and (ii) the ratio of MFI SARS-CoV-2/MFI
179 mock must be higher than 3.

180 We evaluated the assay specificity and sensitivity with a set of 180 historic diagnostic
181 samples that had not been analysed for antibody responses to endemic HCoV, with 21 sera
182 derived from eight patients with confirmed endemic HCoV infections (pre- and post-infection
183 sera sampled), as well as with 60 sera from SARS-CoV-2 PCR-positive individuals (Table 1).
184 The results for IgM and IgG (MFI SARS-CoV-2/MFI mock ratios) are shown for a
185 representative set of specimen in figure 2 and a summary of all sera tested for S-specific
186 antibody responses is provided in table 1. With the cut-off criteria defined above, 60 out of 60
187 specimen collected from PCR-confirmed SARS-CoV-2 patients were IgG-positive (100%)
188 and 48 out of 55 were tested IgM-positive (84.2%; not all samples characterized for IgM). Of
189 note, the negative testing for IgM occurred in serum samples, which were still IgG positive
190 and sampled most probably in the later stage of convalescence. Regarding the specificity of
191 the assay, IgM exceeded the cut-off criteria only in patients with a previously PCR-confirmed
192 SARS-CoV-2 infection, while none of the sera from uninfected individuals did so (0/105). For
193 IgG, two out of 180 sera (1.1 %) sampled in the pre-COVID-19 era without any information
194 about HCoV status surpassed the criteria for seroconversion. Importantly, none of the sera
195 with a PCR-confirmed endemic HCoV infection (sampled 2-4wks post-infection) showed any
196 IgG or IgM cross-reactivity, thus, indicating a high degree of assay specificity for SARS-
197 CoV-2 seroconversion.

198 A longitudinal analysis of a patient starting at the day of PCR-confirmed SARS-CoV-2
199 infection (3th April, day 0) presented specific seroconversion for IgG around day 8 (11th April)
200 and for IgM around day 10 (13th April) although showing elevated levels of IgM below the
201 cut-off already earlier (Fig. 3A). A second patient presented earlier IgM (day 3, 30th March)
202 than IgG seroconversion (day 7; Fig. 3B), but it is important to note that the exact infection
203 events are unknown in both cases.

204 **Performance compared to commercial kits**

205 We further assessed thirteen serum samples from PCR-confirmed cases of SARS-CoV-2
206 infections in a comparative analysis with our flow cytometric assay, a commercial ELISA for
207 IgA/IgG (spike subunit S1-specific; EuroImmun), and a commercial CLIA (N- and S-specific;
208 Shenzhen Yhlo Biotech). Among those thirteen samples, eight were positive for SARS-CoV-
209 2-specific antibodies in all assays, while two specimens were uniformly negative (Table 2).
210 Of note, those two sera were sampled at the day of PCR-confirmation, thus, seroconversion
211 might not yet have been occurred. Similarly, another specimen (sample 3) was sampled at the
212 same day as the first positive PCR test and showed IgG/IgM seroconversion in the flow
213 cytometric assay, but did not show reactivity in the CLIA and only borderline reactivity in the
214 IgG ELISA (“borderline” as defined by manufacturer). The flow cytometric serological assay
215 for IgG and IgM as well as the ELISA for IgA showed the highest sensitivity with 11/13
216 specimens above the cut-off. Two sera were borderline positive in the IgG ELISA, while both
217 positive in the flow cytometric assay and one positive in the IgG CLIA. Overall, this
218 demonstrates a high sensitivity of our cytometric antibody detection for seroconversion in a
219 direct comparison to commercially available detection kits. The lower detection limit was also
220 confirmed by serial dilutions of selected positive samples. While 1-10,000 dilutions were still
221 measured as seropositive by our flow cytometric assay, the two other kits revealed a negative
222 result suggesting a higher analytical sensitivity of the flow cytometric test (data not shown).

223 **ACE-2-Fc as external standard for absolute quantification of samples**

224 In order to allow quantitation of antibody responses, we developed an external standard based
225 on the soluble SARS-CoV-2 entry receptor ACE-2 (12,14) fused to a human IgG fragment
226 crystallizable region (Fc region). As depicted in figure 4A, the ACE-2-Fc standard binds to
227 SARS-CoV-2-expressing HEK 293T cells in a concentration-dependent manner with a linear
228 incline before a saturation phase at higher concentrations. The MFIs of the standard curve
229 demonstrate a strong reproducibility with low inter-assay variation (Fig. 4A) and allow

230 absolute quantitation of in-house standard sera or plasma. The anti SARS-CoV-2 IgG
231 concentration in our standard plasma was determined using the linear range of the
232 recombinant ACE2-Fc protein as standard. After adjustment for molecular weight differences,
233 the standard plasma had a concentration of 1.01 mg/ml anti-SARS-CoV-2 S IgG. Aliquots of
234 this plasma sample were used as standards for quantification of seven randomly selected sera
235 in the flow cytometric assay (Fig. 4B) and the EuroImmun ELISA (Fig. 4C), respectively.
236 This revealed a good correlation for the two quantification methods (Fig. 4 D). Within PCR-
237 positive individuals, the flow cytometric assay could monitor serum antibody responses to the
238 SARS-CoV-2 S protein in the range of 10 μ g/ml (mild cases) up to 6 mg/ml in severely sick
239 patients. Thus, this quantification provides an objective value of SARS-CoV-2 spike-binding
240 IgG concentrations in a given sample that can be compared among different assays and
241 laboratories.

242 **Discussion**

243 While rigorous measures led to a partial control of the recent SARS-CoV-2 pandemic in some
244 countries, validated serological assays are urgently needed to consolidate those achievements
245 and to support the transition to a post-peak phase. This includes for example diagnostic
246 measures for late/post infection stages, COVID-19 contact tracing, the assessment of
247 epidemiological aspects, and the evaluation of immunity after infection or in potential vaccine
248 trials. In the recent study, we validated an in-house flow cytometric assay for the detection of
249 SARS-CoV-2 S-specific IgM and IgG using sera from PCR-confirmed COVID-19 cases and
250 a collection of control serum samples. In regard to specificity and sensitivity, our flow
251 cytometric assay showed a comparable or even better performance compared to commercial
252 CE-marked serological assays (EuroImmun ELISA and Shenzhen Yhlo CLIA).

253 Detection of viral nucleic acids via real time PCR is the gold standard in the diagnosis of
254 acute SARS-CoV-2 infections. However, despite its reliability early during infection,

255 confirmation of an infection at later time points becomes less reliable. As early as eight days
256 post-infection, the diagnostic value of serological assays might therefore outperform nucleic-
257 acid-based methods (15,16). Indeed, also our study showed seroconversion in a longitudinal
258 set of sera from one patient eight days after the first positive PCR test, although the exact
259 infection date is not clearly defined. As reported before (15,17,18), IgM did not generally
260 possess a higher clinical sensitivity compared to IgG, since most of the seropositive specimen
261 tested in the present study were positive for both isotypes. Detection of SARS-CoV-2-specific
262 IgA was previously reported as more sensitive than detection of IgG in the EuroImmun
263 ELISA kits (19). However, while this held also true in our study, IgG and IgM measured by
264 the flow cytometric assay were similarly sensitive compared to the IgA ELISA. This higher
265 sensitivity to detect S-specific IgG might be due to the different viral antigens used in the
266 assays. Our flow cytometric assay exploits full-length S protein in its natural conformation
267 and with the respective posttranslational modifications due to the expression in mammalian
268 cells. This enables detection of the full spectrum of S-specific antibodies directed against
269 conformational epitopes and glycosylated sites as well, some immunogenic sites possibly
270 missing in truncated, recombinant S1-only proteins as used in the EuroImmun ELISA.

271 A potential downside of using full-length S for serological testing might be the detection of
272 cross-reactive antibodies induced by other HCoV. Along this line, some assays detect only
273 antibodies directed against the S1 subunit (like the EuroImmun ELISA) or the receptor
274 binding domain in order to increase specificity (19,20). However, in a collection of sera from
275 individuals that suffered from an infection with an endemic HCoV shortly before blood
276 collection, none was tested positive for SARS-CoV-2 antibodies. In additional 180 specimens
277 sampled before the COVID-19 outbreak, two sera were found to be reactive in the flow
278 cytometric assay. Since endemic HCoV seroprevalence is high in the general population (11)
279 and those two individuals were non-reactive in the commercial S1-specific ELISA, a plausible
280 explanation is cross-reaction of antibodies induced by the endemic HCoVs with the S2

281 subunit of SARS-CoV-2. Although the reactivity of the two specimens need to be classified as
282 false-positive detection of SARS-CoV-2 antibodies, these cross-reactive antibodies might
283 possess antiviral activity against COVID-19 and the analysis of cross-protection due to these
284 responses might be an interesting topic for further investigations. Although a clinical
285 specificity of about 99% seems high, the positive predictive value of commonly used antibody
286 tests under the currently expected SARS-CoV-2 seroprevalence rates in many countries of 1-
287 2% is low. While this may be controlled for in seroepidemiological studies, confirmatory tests
288 are urgently needed if serological assays are to be used for individual diagnosis of past SARS-
289 CoV-2 infections.

290 Regarding the clinical sensitivity, the flow cytometric serology assay detected 100% of IgM
291 and IgG positive samples measured by either of the two commercial assays. Only in cases
292 where blood samples were taken at the same day as PCR sampling, all assays (ELISA, CLIA,
293 cytometry) were negative, probably reflecting acute infections prior to development of
294 detectable antibody responses. The lower analytical detection limit of the flow cytometric
295 assay is consistent with its excellent clinical sensitivity.

296 As the demand for SARS-CoV-2 serology testing kits increases worldwide and only a limited
297 number of suppliers have developed such kits yet, there is a high need to expand the portfolio
298 of serology techniques to meet this demand. The flow cytometry-based technique to detect
299 SARS-CoV-2 seroconversion presented here, fulfils fundamental criteria in regard to
300 sensitivity, specificity, and robustness. Therefore, we think that this method combines a
301 moderate workload without the need for critical components and the possibility for high-
302 throughput testing and, thus, can expand the existing portfolio. The basic requirements needed
303 like cell culture, plastic ware, and a flow cytometer are available in many standard diagnostic
304 and biomedical research labs. Thus, this method can increase serology testing capacities
305 significantly without competing for ELISA/CLIA kits. Given the large number of antibody

306 assays reaching the market without clearly defined analytical sensitivities, using recombinant
307 ACE-2 Fc protein for standardization is a potential strategy for cross-assay comparisons.
308 Moreover, the quantification of S-specific antibody responses might help to define protective
309 antibody levels as correlate of protective immunity.

310 In conclusion, our in-house flow cytometry-based serological assay has good specificity and
311 sensitivity for the detection of antibodies to SARS-CoV-2. In addition to the nucleotide
312 sequence of the antigen, only readily available reagents were needed to establish the assay.
313 Therefore, the flow cytometric assay may also serve as a rapid-response antibody test against
314 other emerging viral infections.

315 **References**

- 316 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
317 infected with 2019 novel coronavirus in Wuhan, China. *Lancet* [Internet]. 2020
318 Feb;395(10223):497–506. Available from:
319 <https://linkinghub.elsevier.com/retrieve/pii/S0140673620301835>
- 320 2. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report -
321 105 [Internet]. 2020. Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2)
322 [source/coronaviruse/situation-reports/20200504-covid-19-sitrep-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2)
323 [105.pdf?sfvrsn=4cdda8af_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2)
- 324 3. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-
325 nCoV and naming it SARS-CoV-2. *Nat Microbiol* [Internet]. 2020 Apr 2;5(4):536–44.
326 Available from: <http://www.nature.com/articles/s41564-020-0695-z>
- 327 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
328 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*
329 [Internet]. 2020 Jan 23;25(3). Available from:
330 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045>
- 331 5. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human
332 Coronaviruses. In 2018. p. 163–88. Available from:
333 <https://linkinghub.elsevier.com/retrieve/pii/S0065352718300010>

- 334 6. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al.
335 Contributions of the structural proteins of severe acute respiratory syndrome
336 coronavirus to protective immunity. *Proc Natl Acad Sci* [Internet]. 2004 Jun
337 29;101(26):9804–9. Available from:
338 <http://www.pnas.org/cgi/doi/10.1073/pnas.0403492101>
- 339 7. Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R, et al. Antibody responses to individual
340 proteins of SARS coronavirus and their neutralization activities. *Microbes Infect*
341 [Internet]. 2005 May;7(5–6):882–9. Available from:
342 <https://linkinghub.elsevier.com/retrieve/pii/S1286457905000869>
- 343 8. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses:
344 Challenges and pitfalls. *Virus Res* [Internet]. 2014 Dec;194:175–83. Available from:
345 <https://linkinghub.elsevier.com/retrieve/pii/S0168170214001257>
- 346 9. Ehrengut W, Sarateanu DE. A two year serological surveillance of coronavirus
347 infections in Hamburg. *Infection* [Internet]. 1980 Mar;8(2):70–2. Available from:
348 <http://link.springer.com/10.1007/BF01639150>
- 349 10. Severance EG, Bossis I, Dickerson FB, Stallings CR, Origoni AE, Sullens A, et al.
350 Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and
351 Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan Population.
352 *Clin Vaccine Immunol* [Internet]. 2008 Dec;15(12):1805–10. Available from:
353 <https://cvi.asm.org/content/15/12/1805>
- 354 11. Gorse GJ, Patel GB, Vitale JN, O’Connor TZ. Prevalence of Antibodies to Four
355 Human Coronaviruses Is Lower in Nasal Secretions than in Serum. *Clin Vaccine*
356 *Immunol* [Internet]. 2010 Dec;17(12):1875–80. Available from:
357 <https://cvi.asm.org/lookup/doi/10.1128/CVI.00278-10>
- 358 12. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.
359 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
360 Clinically Proven Protease Inhibitor. *Cell* [Internet]. 2020 Apr;181(2):271–280.e8.
361 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867420302294>
- 362 13. Hahn A, Birkmann A, Wies E, Dorer D, Mahr K, Stürzl M, et al. Kaposi’s Sarcoma-
363 Associated Herpesvirus gH/gL: Glycoprotein Export and Interaction with Cellular
364 Receptors. *J Virol* [Internet]. 2009 Jan 1;83(1):396–407. Available from:
365 <https://jvi.asm.org/content/83/1/396>

- 366 14. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of
367 SARS-CoV-2 by full-length human ACE2. *Science* (80-) [Internet]. 2020 Mar
368 27;367(6485):1444–8. Available from:
369 <https://www.sciencemag.org/lookup/doi/10.1126/science.abb2762>
- 370 15. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-
371 CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* [Internet]. 2020
372 Mar 28; Available from: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa344/5812996)
373 [article/doi/10.1093/cid/ciaa344/5812996](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa344/5812996)
- 374 16. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral
375 Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*
376 [Internet]. 2020 Mar 21; Available from: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa310/5810754)
377 [article/doi/10.1093/cid/ciaa310/5810754](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa310/5810754)
- 378 17. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal
379 profiles of viral load in posterior oropharyngeal saliva samples and serum antibody
380 responses during infection by SARS-CoV-2: an observational cohort study. *Lancet*
381 *Infect Dis* [Internet]. 2020 Mar; Available from:
382 <https://linkinghub.elsevier.com/retrieve/pii/S1473309920301961>
- 383 18. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al.
384 Breadth of concomitant immune responses prior to patient recovery: a case report of
385 non-severe COVID-19. *Nat Med* [Internet]. 2020 Apr 16;26(4):453–5. Available from:
386 <http://www.nature.com/articles/s41591-020-0819-2>
- 387 19. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.
388 Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in
389 Coronavirus Disease 2019 Patients. *Emerg Infect Dis* [Internet]. 2020 Jul;26(7).
390 Available from: http://wwwnc.cdc.gov/eid/article/26/7/20-0841_article.htm
- 391 20. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt KA, et al.
392 Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* [Internet]. 2020
393 Jan 1;2020.04.09.20056325. Available from:
394 <http://medrxiv.org/content/early/2020/04/10/2020.04.09.20056325.abstract>
- 395
- 396

397 Table 1. Validation of the flow cytometric assay for SARS-CoV-2-specific IgM and IgG with
 398 serum samples collected before the COVID-19 outbreak and a set of sera from PCR-
 399 confirmed SARS-CoV-2 infections

	Samples (# of patients)	IgM+ (%)*	IgM- (%)*	IgG+ (%)	IgG- (%)
Pre-COVID-19 sera	180 (n.d.)	0 (0)	84 (100)	2 (1.1)	178 (98.8)
HCoV+ (endemic, pre)	8 (8)	0 (0)	8 (100)	0 (0)	8 (100)
HCoV+ (endemic, post)	13 (8)	0 (0)	13 (100)	0 (0)	13 (100)
Recent SARS-CoV-2 PCR+	60 (34)	48 (87.3)	7 (12.7)	60 (100)	0 (0)

400 n.d., not determined. *, IgM testing was not available for initial tests, which explains the
 401 lower sample number


402

403 Table 2: Analysis of serum samples from COVID-19-infected individuals at various time
 404 points relative to PCR-confirmation by EuroImmune ELISA, in-house flow cytometric assay,
 405 and Yhlo CLIA

Sample	Sampling relative to PCR [days]	EuroImmune ELISA				Flow cytometry assay				Yhlo CLIA			
		IgA	IgA Ratio	IgG	IgG Ratio	IgM	IgM Ratio	IgG	IgG Ratio	IgM	AU/ml	IgG	AU/ml
1	0	-	0.4	-	0.2	-	1.9	-	3.1	-	0.54	-	0.52
2	0	-	0.1	-	0.2	-	1.2	-	0.95	-	1.18	-	2.29
3	0	+	1.9	+/-	0.9	+	9	+	24.1	-	5.46	-	1.72
4	0	+	3	+	2.7	+	17	+	90.7	+	362.64	+	30.94
5	+2	+	4.5	+	4.5	+	22.2	+	160	+	104.09	+	49.6
6	+5	+	≥11	+	9.4	+	41	+	112.6	+	254.86	+	61.55
7	+6	+	≥11	+	9.4	+	42.7	+	166.3	+	605.83	+	47.87
8	+7	+	≥11	+	14.5	+	15.4	+	95.9	+	15.47	+	112.52
9	+8	+	≥11	+	12.6	+	56	+	263.3	+	246.58	+	101.62
10	+8	+	4.8	+/-	0.8	+	31	+	103.4	-	6.48	+	16.94
11	+9	+	≥11	+	15.7	+	52	+	321.8	+	106.43	+	161.04
12	+12	+	10.1	+	5.6	+	48.3	+	345.5	+	43.27	+	186.03
13	+14	+	≥11	+	14	+	37.1	+	261.5	-	7.76	+	155.16
Reactivity		11/13		9/13		11/13		11/13		8/13		10/13	


406

407 * Time gap between SARS-CoV-2 diagnosis by PCR and collection of blood sample. AU,
 408 arbitrary units. +, seropositive. -, seronegative. +/-, borderline. Ratios for IgG and IgA ELISA
 409 indicate the ratio between sample and calibrator. Ratios for the flow cytometric assay indicate
 410 the ratio between mock MFI and SARS-CoV-2 MFI for a given sample. Red/orange
 411 background indicates negative/borderline result.




412

413 Figure 1. Representative samples measured in the flow cytometric assay. As described in the
 414 methods section, 293T cells expressing SARS-CoV-2 S protein and pcDNA3.1-transfected
 415 cells (mock) were incubated with COVID-19 patient sera (S1-S3) or with negative control
 416 sera (S4-S6). Bound IgM and IgG were detected with secondary detection antibodies. The left
 417 plot shows the gating of the target populations considering the co-transfected fluorescent
 418 proteins as transfection markers (BFP and dsRed). The right histograms depict IgM and IgG
 419 fluorescence signals in each sample for both cell populations, respectively. The mean
 420 fluorescence intensity is shown in numbers.




421

422 Figure 2. Analysis of SARS-CoV-2-specific IgM and IgG in serum samples from uninfected
423 individuals or COVID-19 patients. The flow cytometric serological assay was performed with
424 samples from the pre-COVID-19 era (n=82), samples from individuals with known endemic
425 HCoV infection (n=8 before infection, HCoV (end., pre); n=13 after infection, HCoV (end.,
426 post)), and samples from PCR-positive COVID-19 patients (n=16). Shown are the ratios of
427 the MFI values for SARS-CoV-2-expressing and mock-transfected cells for IgM (a) and IgG
428 (b). The cut-off is depicted as dotted line and represents a ratio of 3. Shown are individual
429 serum samples and the group mean. MFI, mean fluorescence intensity. end, endemic.



430

431 Figure 3. Longitudinal analysis of SARS-CoV-2 seroconversion in two COVID-19 cases. At
432 each depicted date, serum samples were collected from the respective patient and analysed by
433 the flow cytometric assay for IgM and IgG. The cut-off is depicted as dotted line and
434 represents a ratio of the MFI values for SARS-CoV-2-expressing and mock-transfected cells
435 of 3. Arrows indicate values above the cut-off.



436

437 Figure 4. Quantification of SARS-CoV-2-specific antibody levels by an external ACE-2-Fc
438 standard. (A) Defined concentrations of the ACE-2-Fc protein were analysed by the flow
439 cytometric assay in five independent measurements (each symbol representing one
440 measurement). With the help of this ACE-2-Fc standard, the concentration of a standard
441 serum was defined. The standard serum was measured in a dilution series by the flow
442 cytometric assay (B) and the EuroImmun ELISA (C). 4-PL curve fitting (shown with 95%
443 confidence bands) was used to generate a standard curve for the absolute quantification of
444 unknown samples. (D) Seven randomly chosen sera from PCR-confirmed COVID-19 patients
445 were quantified by ELISA and the cytometric assay for SARS-CoV-2-specific IgG. The plot
446 assesses the correlation between those two assays by spearman's rank correlation coefficient.